Comparison of survival results of patients with T0\nand T1-2-3 in pathological T staging in patients with\nnon-small cell lung cancer who underwent surgery\nafter neoadjuvant treatment

OpenAlex English

Aim: In this study, we aimed to compare the survival results of patients who underwent neoadjuvant treatment with NSCLC between March 1997 and August 2014 and were found to have T0N0 and T1-2-3/N0.Material and methods: A hundred ninety-five patients who had complete neoadjuvant therapy, complete lung resection and lymph node dissection, and pathologically diagnosed as T0 or T1-2-3/N0, M0 were included in the study.Results: Of the 195 patients included in the study, 181 were male, 14 were female and the mean age of the patients was 57.9.The mean age of the groups was as follows: group 1: 58.1, group 2: 57.7, group 3: 59.7 and group 4: 56.8.In our series the most common complication was atelectasis (n = 19).Others were prolonged air leak (n = 16), pneumonia (n = 12), apical pleural space (n = 6), wound infection (n = 3), cardiac problems (n = 3), hematoma (n = 3), bronchopleural fistula (n = 3), empyema (n = 2), chylothorax (n = 1).The 5-year survival rate for patients in the T0N0 group was 76.3%.This rate was 71.8% in group 2, 63.6% in group 3 and 44.1% in group 4. Conclusions: Survival was found to be better in patients who underwent surgery after neoadjuvant therapy and had a complete pathological response.We believe that we can provide better results with the increase in the number of cases detected as TxN0 after the neoadjuvant treatment and prolongation of the follow-up period. Key words: non-small